1-Docosanol: Difference between revisions

Browse history interactively
Page 1
Page 2
← Previous edit
Content deleted Content added
VisualWikitext
CheMoBot (talk | contribs)
Bots
141,565 edits
Updating {{chembox}}, {{drugbox}} (no changed fields - added verified revid - updated 'ChEMBL_Ref') per Chem/Drugbox validation (report errors or [[user t
SdkbBot (talk | contribs)
Bots
347,239 edits
 
(129 intermediate revisions by 73 users not shown)
Line 1: Line 1:
{{Use dmy dates|date=October 2022}}
{{Chembox
{{Chembox
| Verifiedfields = changed
| verifiedrevid = 417863980
| Watchedfields = changed
| ImageFile1 = Docosan-1-ol.svg
| verifiedrevid = 419109485
| ImageName1 = Wireframe model of docosanol
| ImageFile2 = Docosanol-3D-vdW.png
| ImageFile1 = Docosan-1-ol.svg
| ImageFile1_Ref = {{chemboximage|correct|??}}
| ImageName2 = Spacefill model of docosanol
| ImageSize1 = 244
| IUPACName = Docosan-1-ol
| ImageName1 = Skeletal formula of docosanol
| OtherNames = Abreva<br />
| ImageFile2 = Docosanol-3D-vdW rotated.png
Behenic alcohol<br />
| ImageFile2_Ref = {{chemboximage|correct|??}}
Behenyl alcohol<br />
| ImageSize2 = 244
Cachalot BE-22<br />
| ImageName2 = Spacefill model of docosanol
Dehydag wax 22 (lanette)<br />
| PIN = Docosan-1-ol<ref name = "docosan-1-ol (CHEBI:31000)" >{{Cite web|url = http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31000|title = Docosan-1-ol (CHEBI:31000)|work = Chemical Entities of Biological Interest (ChEBI)|location = UK|publisher = European Bioinformatics Institute|access-date = 26 July 2011|archive-date = 4 August 2014|archive-url = https://web.archive.org/web/20140804191939/http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31000|url-status = live}}</ref>
1-Docosanol<br />
| OtherNames = {{unbulleted list|
''n''-Docosanol<br />
Docosyl alcohol<br />
*Behenic alcohol<ref name = "docosan-1-ol (CHEBI:31000)" />
*Behenyl alcohol<ref name = "docosan-1-ol (CHEBI:31000)" />
Emery 3304<br />
*Cachalot BE-22{{Citation needed|date = July 2011}}
Lidakol<br />
*1-Docosanol<ref name="chemical book">{{Cite web |url=http://www.chemicalbook.com/ChemicalProductProperty_EN_CB6219657.htm |title=Chemical Book: *1-Docosanol |access-date=26 July 2011 |archive-date=30 June 2013 |archive-url=https://web.archive.org/web/20130630073150/http://www.chemicalbook.com/ChemicalProductProperty_EN_CB6219657.htm |url-status=live }}</ref>
Loxiol VPG 1451
*''n''-Docosanol<ref name="chemical book" />
| Section1 = {{Chembox Identifiers
*Docosyl alcohol<ref name = "docosan-1-ol (CHEBI:31000)" />
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
*Emery 3304<ref name="chemical book" />
| StdInChI = 1S/C22H46O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h23H,2-22H2,1H3
*Loxiol VPG 1451{{Citation needed|date = July 2011}}
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
}}
| StdInChIKey = NOPFSRXAKWQILS-UHFFFAOYSA-N
|Section1={{Chembox Identifiers
| CASNo = 661-19-8
| CASNo = 661-19-8
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo_Ref = {{cascite|correct|CAS}}
| CASOther = 30303-65-2
| PubChem = 12620
| PubChem = 12620
| ChemSpiderID = 12100
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| PubChem_Ref = {{Pubchemcite}}
| UNII = 9G1OE216XY
| ChemSpiderID = 12100
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| UNII_Ref = {{fdacite|correct|FDA}}
| EINECS = 211-546-6
| EINECS = 211-546-6
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00632
| DrugBank = DB00632
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03884
| KEGG = D03884
| KEGG_Ref = {{keggcite|correct|kegg}}
| MeSHName = Docosanol
| ChEBI = 31000
| MeSHName = docosanol
| ChEBI_Ref = {{ebicite|correct|EBI}}
| RTECS = JR1315000
| ChEBI = 31000
| ATCCode_prefix = D06
| ChEMBL = 1200453
| ATCCode_suffix = BB11
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| SMILES = OCCCCCCCCCCCCCCCCCCCCCC
| RTECS = JR1315000
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 9G1OE216XY
| Beilstein = 1770470
| SMILES = CCCCCCCCCCCCCCCCCCCCCCO
| StdInChI = 1S/C22H46O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h23H,2-22H2,1H3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| InChI = 1/C22H46O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h23H,2-22H2,1H3
| InChI = 1/C22H46O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h23H,2-22H2,1H3
| InChIKey = NOPFSRXAKWQILS-UHFFFAOYAB
| StdInChIKey = NOPFSRXAKWQILS-UHFFFAOYSA-N
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| Beilstein = 1770470}}
| InChIKey = NOPFSRXAKWQILS-UHFFFAOYAB
| Section2 = {{Chembox Properties
}}
| C = 22
|Section2={{Chembox Properties
| H = 46
| O = 1
| C=22 | H=46 | O=1
| MeltingPtK = 343
| ExactMass = 326.354866094 g mol<sup>-1</sup>
| MeltingPtC = 71
| BoilingPtK = 453
| BoilingPt_notes = at 29&nbsp;Pa
| BoilingPtC = 180}}
| LogP = 10.009
| Section3 = {{Chembox Pharmacology
}}
| AdminRoutes = Topical
| Section6 = {{Chembox Pharmacology
| Legal_US = OTC
| Pharmacology_ref =
| PregCat_US = B}}
| ATCCode_prefix = D06
| ATCCode_suffix = BB11
| ATC_Supplemental =
| ATCvet =
| Licence_EU =
| INN =
| INN_EMA =
| Licence_US =
| Legal_status =
| Legal_AU =
| Legal_AU_comment =
| Legal_CA =
| Legal_CA_comment =
| Legal_NZ =
| Legal_NZ_comment =
| Legal_UK =
| Legal_UK_comment =
| Legal_US = OTC
| Legal_US_comment = <ref name="Abreva FDA label">{{cite web | title=Abreva- docosanol cream | website=DailyMed | date=18 April 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf02c8c5-af60-41f1-a202-38a97491a720 | access-date=14 October 2022 | archive-date=14 October 2022 | archive-url=https://web.archive.org/web/20221014040530/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf02c8c5-af60-41f1-a202-38a97491a720 | url-status=live }}</ref><ref name="Abreva Approval Package">{{cite web | title=Drug Approval Package: Abreva (Docosanol) NDA #20-941 | website=U.S. [[Food and Drug Administration]] (FDA) | date=21 August 2001 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-941_Abreva.cfm | access-date=13 October 2022 | archive-date=14 October 2022 | archive-url=https://web.archive.org/web/20221014040518/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-941_Abreva.cfm | url-status=live }}</ref>
| Legal_EU = Rx-only
| Legal_EU_comment = <ref name="docosanol PSUSA">{{cite web |title=List of nationally authorised medicinal products |url=https://www.ema.europa.eu/en/documents/psusa/docosanol-list-nationally-authorised-medicinal-products-psusa/00010092/202104_en.pdf |website=ema.europa.eu |publisher=European Medicines Agency |access-date=23 October 2022 |archive-url=https://web.archive.org/web/20221015233411/https://www.ema.europa.eu/en/documents/psusa/docosanol-list-nationally-authorised-medicinal-products-psusa/00010092/202104_en.pdf |archive-date=15 October 2022 |language=en |date=2 December 2021 |url-status=live}}</ref>
| Legal_UN =
| Legal_UN_comment =
| Pregnancy_category =
| Pregnancy_AU =
| Pregnancy_AU_comment =
| Dependence_liability =
| AdminRoutes = [[Topical administration|Topical]]
| Bioavail =
| ProteinBound =
| Metabolism =
| Metabolites =
| OnsetOfAction =
| HalfLife =
| DurationOfAction =
| Excretion =
}}
}}
}}


'''1-Docosanol''', also known as '''behenyl alcohol''', is a [[Saturated and unsaturated compounds|saturated]] [[fatty alcohol]] containing 22 carbon atoms, used traditionally as an [[Moisturizer|emollient]], [[Emulsifier#Emulsifiers|emulsifier]], and thickener in cosmetics.<ref>{{cite web|url=https://ec.europa.eu/growth/tools-databases/cosing/?fuseaction=search.details_v2&id=74589|title=CosIng: Behenyl alcohol|publisher=[[European Commission]]|accessdate=14 March 2021|archive-date=27 August 2021|archive-url=https://web.archive.org/web/20210827200639/https://ec.europa.eu/growth/tools-databases/cosing/?fuseaction=search.details_v2&id=74589|url-status=live}}</ref>
'''Docosanol''', also known as '''behenyl alcohol''', is a [[saturation (chemistry)|saturated]] [[fatty alcohol]]<ref name="pmid1660151">{{Cite journal|author=Katz DH, Marcelletti JF, Khalil MH, Pope LE, Katz LR |title=Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=88 |issue=23 |pages=10825–9 |year=1991 |month=December |pmid=1660151 |pmc=53024 |doi= 10.1073/pnas.88.23.10825|url=http://www.pnas.org/cgi/pmidlookup?view=long&pmid=1660151}}</ref> used traditionally as an emollient, emulsifier, and thickener in cosmetics,<ref>http://fleur-s-cosmetics.stalgroup.com/</ref><ref>http://www.korresusa.com/product/4820/eye-cream/skincare/category/anti-aging-</ref><ref>http://www.avalonorganics.com/?id=124&show=B</ref> nutritional supplement (as an individual entity and also as a constituent of [[polyicosanol]]), and more recently, in a [[Food and Drug Administration]] (FDA) approved pharmaceutical, '''Abreva''',<ref>[http://www.medilexicon.com/drugs/abreva.php mediLexicon: Docosanol]</ref> approved as an [[antiviral agent]] for reducing the duration of [[cold sore]]s caused by the [[herpes simplex virus]].


In July 2000, docosanol was approved for medical use in the United States as an [[antiviral agent]] for reducing the duration of [[cold sore]]s.<ref name="Abreva FDA label" /><ref name="Abreva Approval Package" /><ref name="pmid1660151">{{Cite journal|vauthors=Katz DH, Marcelletti JF, Khalil MH, Pope LE, Katz LR |title=Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=88 |issue=23 |pages=10825–10829 |date=December 1991 |pmid=1660151 |pmc=53024 |doi= 10.1073/pnas.88.23.10825|bibcode=1991PNAS...8810825K |doi-access=free }}</ref> It is an [[over-the-counter medication]] (OTC). It is sold under the brand name '''Abreva''' among others.<ref name="Abreva FDA label" /><ref name="docosanol PSUSA" /><ref name="AC" /><ref>{{Cite web |url=http://www.medilexicon.com/drugs/abreva.php |title=mediLexicon: Docosanol |access-date=2 September 2008 |archive-date=10 March 2013 |archive-url=https://web.archive.org/web/20130310114409/http://www.medilexicon.com/drugs/abreva.php |url-status=dead }}</ref>
==Mechanism and history of antiviral drug usage ==
The presumed mechanism of action in docosanol is by inhibiting the fusion of the human host cell with the [[viral envelope]] of the herpes virus, thus preventing its [[viral replication|replication]]. This mechanism has neither been directly observed nor proven, however.

The drug was licensed as an oral herpes medicine after clinical trials by the FDA in July 2000.<ref>{{Cite web| title = Drug Name: ABREVA (docosanol) - approval | work = | publisher = centerwatch.com | date = July 2000 | url = http://www.centerwatch.com/patient/drugs/dru627.html| doi = | accessdate = 2007-10-17 }}</ref>
It was shown to shorten the healing by 17.5 hours on average (95% [[confidence interval]]: 2 to 22 hours) in a placebo-controlled trial.<ref>{{Cite journal|last=Sacks|first=SL|title=Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial|publisher=J Am Acad Dermatol|volume=45|issue=2|pages=222–230}}</ref> Three other trials showed negative results, but these were not published.<ref>Schubert-Zsilavecz, M, Wurglics, M, ''Neue Arzneimittel 2008/2009''</ref>

Marketed by Avanir Pharmaceuticals, Abreva was the first [[over-the-counter]] [[antiviral drug]] approved for sale in the [[United States]] and [[Canada]]. In Europe, it is marketed by Healthcare Brands under the name '''Erazaban'''. In March 2007 it was the subject of a US nationwide class-action suit against Avanir and GlaxoSmithKline as the claim that it cut recovery times in half was found to have been misleading in a California court, but the case was eventually settled and the "cuts healing time in half" claim had not been used in product advertising for some years.<ref>{{Cite web| title = California Court Upholds Settlement Of Class Action Over Cold Sore Medicationl | work = | publisher = BNA Inc. | date = July 2000 | url = http://subscript.bna.com/SAMPLES/plp.nsf/85256269004a991e8525611300214487/29d5bb623a50fd25852572ad0074f772?OpenDocument | format = | doi = | accessdate = 2007-10-17 |archiveurl = http://web.archive.org/web/20080205070115/http://subscript.bna.com/SAMPLES/plp.nsf/85256269004a991e8525611300214487/29d5bb623a50fd25852572ad0074f772?OpenDocument |archivedate = 2008-02-05}}</ref>


==Side effects==
==Side effects==
One of the most common side effects that has been reported from docosanol is [[headache]]. Headaches caused by the medication tend to be mild and can occur in any region of the head.<ref name="Abreva Side Effects">{{Cite web|url=http://www.livestrong.com/article/112151-abreva-side-effects/|publisher=Livestrong.com|title=Abreva Side Effects|access-date=20 May 2010|archive-date=23 May 2010|archive-url=https://web.archive.org/web/20100523015616/http://www.livestrong.com/article/112151-abreva-side-effects/|url-status=live}}</ref> In clinical trials, headache occurred in 10.4% of people treated with docosanol cream and 10.7% of people treated with [[placebo]].<ref name="AC" />


The most serious side effects, although rare, are allergic reactions. Some of the patients experienced the symptoms of allergic reactions, including [[difficulty breathing]], [[confusion]], [[angioedema]] (facial swelling), [[fainting]], [[dizziness]], [[hives]] or [[chest pain]].<ref name="Abreva Side Effects"/>
[[Side effects]] from the drug, if they occur, may go away during treatment as the body adjusts to it, otherwise a physician should be consulted.<ref name="SideEffects">{{Cite web|url=http://www.mayoclinic.com/health/drug-information/DR600565/DSECTION=side-effects| title=Side Effects|date=|accessdate=2010-05-20}}</ref>


Other side effects may include: [[acne]], burning, dryness, [[itching]], [[rash]], redness, acute [[diarrhea]], [[soreness]], swelling.<ref name="Side Effects">{{Cite web|url=https://www.drugs.com/cons/docosanol-topical.html/|publisher=Drugs.com|title=Side Effects|access-date=2010-05-20|archive-date=11 May 2008|archive-url=https://web.archive.org/web/20080511134513/http://www.drugs.com/cons/docosanol-topical.html|url-status=live}}</ref>
One of the most common side effects that has been reported from docosanol is [[headache]]. Headaches caused by the drug tend to be mild and can occur in any region of the head. The intensity of the pain can, in some cases, interfere with the ability of remaining focused when working or when at school.<ref name="Abreva Side Effects">{{Cite web|url=http://www.livestrong.com/article/112151-abreva-side-effects/| title=Abreva Side Effects|date=|accessdate=2010-05-20}}</ref> If headaches develop while using the ointment, one is recommended to take an over-the-counter medication such as [[paracetamol]] to alleviate the [[pain]].


==Mechanism of action==
Skin irritation may also occur at the site of application. Usually, skin irritation is mild to moderate and does not need any further treatment. It may also diminish after prolonged use of docosanol.
Docosanol is thought to work by interfering with and stabilizing the host cell's surface phospholipids, preventing the fusion of the herpes virus's [[viral envelope]] with the human host cell. This disrupted ability of the virus to fuse with the host cell membrane prevents entry and subsequent [[viral replication|replication]].<ref name="pmid34202050">{{cite journal |vauthors=Sadowski LA, Upadhyay R, Greeley ZW, Margulies BJ |title=Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2 |journal=Viruses |volume=13 |issue=7 |date=June 2021 |page=1228 |pmid=34202050 |pmc=8310346 |doi=10.3390/v13071228 |doi-access=free |quote=n-Docosanol is a long-chain, 22-carbon, primary alcohol offered over the counter. It likely inhibits a broad range of enveloped viruses that uncoat at the plasma membrane of target cells. The drug appears to prevent binding and entry of HSVs by interfering directly with the cell surface phospholipids, which are required by the viruses for entry, and stabilizing them. This activity tends to work well against ACV-resistant HSVs and can even act synergistically with other anti-HSV drugs.}}</ref><ref name="AC">{{cite book|title=Austria-Codex| veditors = Haberfeld H |at=Erazaban Creme|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2020|language=German}}</ref><ref name="drugs.com">Docosanol {{Drugs.com|monograph|docosanol}}. Accessed 14 March 2021.</ref>


==History==
The most serious side effects, although rare, are allergic reactions. Some of the patients experienced the symptoms of allergic reactions, including [[difficulty breathing]], [[confusion]], facial [[Swelling (medical)|swelling]], [[fainting]], [[dizziness]], [[hives]] or [[chest pain]].<ref name="Abreva Side Effects"/> Allergic reactions are medical emergencies and individuals who experience them are recommended to seek immediate medical care in order to prevent further complications.
The drug was approved as a cream for oral herpes after clinical trials by the FDA in July 2000.<ref name="Abreva Approval Package" /><ref>{{Cite web | title = Drug Name: Abreva (docosanol) – approval | publisher = centerwatch.com | date = July 2000 | url = http://www.centerwatch.com/patient/drugs/dru627.html | access-date = 17 October 2007 | archive-date = 6 October 2008 | archive-url = https://web.archive.org/web/20081006230140/http://www.centerwatch.com/patient/drugs/dru627.html | url-status = dead }}</ref>
It was shown to shorten the healing by 17.5 hours on average (95% [[confidence interval]]: 2 to 22 hours) in a placebo-controlled trial.<ref>{{Cite journal|last1=Sacks|first1=SL|title=Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial|journal=J Am Acad Dermatol|volume=45|issue=2|pages=222–230|pmid=11464183|doi=10.1067/mjd.2001.116215|year=2001|last2=Thisted|first2=RA|last3=Jones|first3=TM|last4=Barbarash|first4=RA|last5=Mikolich|first5=DJ|last6=Ruoff|first6=GE|last7=Jorizzo|first7=JL|last8=Gunnill|first8=LB|last9=Katz|first9=DH|last10=Khalil|first10=MH|last11=Morrow|first11=Phillip R.|last12=Yakatan|first12=Gerald J.|last13=Pope|first13=Laura E.|last14=Berga|first14=James E.|display-authors=8}}</ref> Another trial showed no effect when treating the infected backs of guinea pigs.<ref name=":0">{{Cite journal
| last1 = McKeough | first1 = MB
| last2 = Spruance | first2 = SL
| title = Comparison of new topical treatments for herpes labialis: Efficacy of penciclovir cream, acyclovir cream, and n-docosanol cream against experimental cutaneous herpes simplex virus type 1 infection
| journal = Archives of Dermatology
| volume = 137
| issue = 9
| pages = 1153–1158
| year = 2001
| pmid = 11559210
| doi=10.1001/archderm.137.9.1153
| doi-access = free}}</ref>


Two experiments with 1-docosanol cream failed to show statistically significant differences by any parameter between 1-docosanol cream and vehicle control–treated sites or between 1-docosanol and untreated infection sites.<ref name=":0" />
Other side effects may include:
* [[Acne]]
* Burning
* Dryness
* [[Itching]]
* [[Rash]]
* Redness
* Acute [[diarrhea]]
* [[Soreness]]
* Swelling.<ref name="SideEffects" />


== Society and culture ==
==Contraindications==
=== Controversy ===
As soon as side effects develop, individuals must interrupt therapy and consult their medical care provider.
In March 2007, it was the subject of a US nationwide class-action suit against Avanir and GlaxoSmithKline as the claim that it cut recovery times in half was found to have been misleading in a California court, but the case was eventually settled and the "cuts healing time in half" claim had not been used in product advertising for some years, instead stating "clinically proven to speed healing".<ref>{{Cite web| title = California Court Upholds Settlement Of Class Action Over Cold Sore Medicationl | publisher = BNA Inc. | date = July 2000 | url = http://subscript.bna.com/SAMPLES/plp.nsf/85256269004a991e8525611300214487/29d5bb623a50fd25852572ad0074f772?OpenDocument | access-date = 17 October 2007 |archive-url = https://web.archive.org/web/20080205070115/http://subscript.bna.com/SAMPLES/plp.nsf/85256269004a991e8525611300214487/29d5bb623a50fd25852572ad0074f772?OpenDocument |archive-date = 5 February 2008}}</ref>

People who are allergic to one of the ingredients of Abreva are recommended to avoid taking this medication. Also, it is not to be used by individuals who suffer from different medical conditions before consulting their health care provider. Interactions with docosanol may occur although there are no known specific interactions at this moment. Therefore, people who are taking other drugs are recommended to first consult their physician and then start the therapy.

This topical has not been yet tested if it is safe to be used by pregnant women. Also, people who are taking other over-the-counter drugs, [[Dietary supplement|supplements]] or herbal preparations are recommended to consult their doctor prior to starting therapy. Nursing mothers are advised to avoid using this topical as it is not established if the active ingredients in the medicine pass into the [[breast milk]]. People who are allergic to docosanol or any other ingredient of the product are strongly advised not to use it.

[[Cosmetics|Cosmetic]] products are recommended to be avoided while using docosanol mainly because they are likely to spread the unhealed [[infection]] and not because they interact with the topical. [[Lipstick]] is not contraindicated but it is recommended to be applied by using a different applicator to prevent spreading of the infection and recurrence. Cosmetics must be removed before applying the ointment. Also, it is important to know that herpes is highly contagious during outbreaks and patients are advised to avoid physical contact with other people as well as sharing the medicine.

Docosanol has not been specifically approved for treatment of children under 12<ref>{{Cite web|url=http://www.drugs.com/cons/docosanol-topical.html/| title= Side Effects|date=|accessdate=2010-05-20}}</ref> but is not expected to produce different side effects or problems than it does in adults. This topical is only intended for external, oral-facial use and should not be administered with the purpose of curing [[genital herpes]] or [[shingles]].

==See also==
*[[Behenic acid]]


==References==
==References==
{{Reflist}}
{{Reflist}}

== External links ==
* [http://www.abreva.com/ Abreva]
* [http://www.drugcite.com?q=ABREVA Abreva adverse events reported to the FDA]


{{alcohols}}
{{alcohols}}
{{Antibiotics and chemotherapeutics for dermatological use}}
{{Antibiotics and chemotherapeutics for dermatological use}}
{{Antivirals}}
{{Antivirals}}
{{Portal bar | Medicine}}


{{DEFAULTSORT:Docosanol, 1-}}
[[Category:Antivirals]]
[[Category:Antiviral drugs]]
[[Category:Fatty alcohols]]
[[Category:Fatty alcohols]]
[[Category:Primary alcohols]]

[[Category:Drugs developed by GSK plc]]
[[da:Docosanol]]
[[es:Docosanol]]
[[Category:Alkanols]]
[[fr:Docosanol]]
[[th:โดโคซานอล]]
Retrieved from "https://en.wikipedia.org/wiki/Special:ComparePages"